BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28291401)

  • 41. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
    Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
    J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?
    Lee CT; Bilton SD; Famiglietti RM; Riley BA; Mahajan A; Chang EL; Maor MH; Woo SY; Cox JD; Smith AR
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):362-72. PubMed ID: 16168831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
    Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Symptomatic osteoradionecrosis of pelvic bones in patients with gynecological malignancies-result of a long-term follow-up.
    Feltl D; Vosmik M; Jirásek M; Stáhalová V; Kubes J
    Int J Gynecol Cancer; 2006; 16(2):478-83. PubMed ID: 16681714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies.
    Georg P; Georg D; Hillbrand M; Kirisits C; Pötter R
    Radiother Oncol; 2006 Jul; 80(1):19-26. PubMed ID: 16766068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
    Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
    Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
    De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
    Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implantation of tissue expander prior to irradiation in the era of intensity modulated radiotherapy: impact on the management of patients with pelvic digestive cancers.
    Ollivier L; Guilloit JM; Dos Santos M; Guillemette L; Florescu C; M'vondo CM; Meyer E; Galais MP; Corbinais S; Parzy A; Varatharajah S; Lesueur P
    Int J Colorectal Dis; 2020 Mar; 35(3):559-564. PubMed ID: 31853620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
    Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients.
    Briere TM; Crane CH; Beddar S; Bhosale P; Mok H; Delclos ME; Krishnan S; Das P
    Radiother Oncol; 2012 Aug; 104(2):161-6. PubMed ID: 22841019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT).
    Durrant L; Robinson M; Hawkins MA; Van den Heuvel F; Muirhead R
    Radiother Oncol; 2016 Oct; 121(1):92-97. PubMed ID: 27576432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy.
    Shih KK; Hajj C; Kollmeier M; Frey MK; Sonoda Y; Abu-Rustum NR; Alektiar KM
    Gynecol Oncol; 2016 Oct; 143(1):18-21. PubMed ID: 27486131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of nodal coverage utilizing image guided radiation therapy for primary gynecologic tumor volumes.
    Ahmed F; Sarkar V; Gaffney DK; Salter B; Poppe MM
    Med Dosim; 2016; 41(3):195-8. PubMed ID: 26994828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.